Project Overview - The project involves the establishment of a thousand-ton bio-based product production line, focusing on 1,3-PDO, calcium lactate, vanillin, and sialic acid processing [3] - The total investment for the project is 50 million yuan, with 5 million yuan allocated for environmental protection [3] - The production capacity upon completion will be 720 tons of 1,3-PDO, 940 tons of calcium lactate, 30 tons of vanillin, and 10 tons of sialic acid annually [3] Company Background - Si Peng Bio-materials (Nantong) Co., Ltd. is a wholly-owned subsidiary of Shanghai Si Peng Technology Co., Ltd., established in May 2022 [4] - The company focuses on negative carbon synthetic biology and is led by a team of scientists from Shanghai Jiao Tong University [4] - It has developed a unique one-step method for synthesizing polylactic acid (PLA) from carbon dioxide, achieving a 70% reduction in carbon emissions [4] - The company has partnered with Angel Yeast to establish a thousand-ton production line, with products including bio-based polyols and biodegradable plastics [4] Industry Insights - The bio-based materials sector is witnessing significant developments, with various companies making strides in bio-manufacturing technologies [8] - The market for bio-based materials is projected to grow substantially, indicating a competitive landscape for companies involved in this field [8]

Core Viewpoint - The article discusses the establishment of a new production line by SiPeng Bio-Materials (Nantong) Co., Ltd., focusing on the production of bio-based products such as 1,3-PDO, calcium lactate, vanillin, and sialic acid, highlighting the company's commitment to sustainable and innovative biomanufacturing practices [1][2]. Group 1: Company Overview - SiPeng Bio-Materials (Nantong) Co., Ltd. was established in July 2024 as a wholly-owned subsidiary of Shanghai SiPeng Technology Co., Ltd., which was founded in May 2022 [1]. - The company focuses on negative carbon synthetic biology and has completed significant funding rounds, including nearly 100 million yuan in a Pre-A round in October 2024 and several million yuan in a Pre-A+ round in May 2025 [1]. Group 2: Production Line Details - The new production line has a total investment of 50 million yuan and is located in the Rugao High-tech Industrial Development Zone [1]. - Upon completion, the production capacity will be 720 tons of 1,3-PDO, 940 tons of calcium lactate, 30 tons of vanillin, and 10 tons of sialic acid annually [1][2]. Group 3: Product Specifications - 1,3-PDO will have a purity of over 99.9% and is intended for use in new textile materials and biodegradable materials, outperforming industry standards [3][4]. - Calcium lactate, a common food additive, is noted for its high bioavailability and mild taste, making it suitable for sensitive populations [6]. - Vanillin produced from biological sources is highlighted for its environmental sustainability and wide applications in food, cosmetics, and pharmaceuticals [8]. - Sialic acid, a natural nine-carbon sugar derivative, is used in various food products, particularly for infants and health supplements [11][12].

Core Insights - The company aims to enhance its market competitiveness in the food, nutrition, and beauty sectors by investing in Peisheng Biotechnology to promote the application of new raw materials in consumer products [1][2] - The establishment of Beijing Kaiyuan Juliy aims to leverage the capital and talent resources in the capital city to improve the company's professional capabilities in business expansion and capital operations, driving a dual strategy of "industry + capital" [1] Product Pricing and Market Strategy - The sales prices of products such as erythritol, blended sugars, and allulose will fluctuate based on specifications, business conditions, and market competition, with a dynamic adjustment throughout the year [1] - The company has a competitive edge in production technology and cost control for tagatose, which is currently in an active promotion phase, with market pricing being continuously optimized based on market feedback [1] New Product Development - The company is committed to innovation-driven growth, focusing on synthetic biology and advancing new product research and industrialization [2] - A new 10,000-ton production line for allulose is under rapid construction, aiming to secure a first-mover advantage in the fast-growing market once approved for domestic use [2] - The existing 85,000-ton erythritol production line is undergoing upgrades to enable flexible manufacturing capabilities across multiple products, significantly reducing new product line construction costs and enhancing market responsiveness [2] - The company is optimizing production processes for high-activity biological raw materials like glycerol glycosides and sweet tea glycosides, with plans for small-scale production based on technology maturity and market demand [2]